Is adjuvant docetaxel useful for prostate cancer?
Study examines its addition to ADT in patients without metastasis
![chemotherapy drip](https://www.ausdoc.com.au/wp-content/uploads/2022/08/Chemotherapy_IV_Tstock-2.jpg)
The addition of docetaxel to ongoing treatment of men who have survived localised therapy for high-risk prostate cancer appears to confer no extra benefit, a study shows.
The French research showed that adding docetaxel to adjuvant androgen deprivation therapy (ADT) in men with biochemical relapse after primary local treatment does not improve radiological progression-free survival.